Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.
COVID survivors
COVID-19
Chronic COVID
Long COVID
Patients with post-COVID-19 syndrome
Post-COVID syndrome
SARS-CoV-2 antibodies
SARS-CoV-2 serology
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
04
03
2021
revised:
20
05
2021
accepted:
22
05
2021
pubmed:
11
6
2021
medline:
16
10
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
To assess the prevalence of and factors associated with post-coronavirus disease 2019 (COVID-19) syndrome 6 months after the onset. A bidirectional prospective study. Interviews investigated symptoms potentially associated with COVID-19 6 months after the disease onset of all consecutive adult inpatients and outpatients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. IgG antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were also evaluated 6 months after the onset of symptoms, at the time of the interview. A total of 599 individuals were included (320 female, 53.4%; mean age 53 years, SD 15.8) and interviewed 187 days (22 SD) after onset. The prevalence of post-COVID-19 syndrome was 40.2% (241/599). The presence of IgG antibodies was significantly associated with the occurrence of post-COVID-19 syndrome (OR 2.56, 95% CI 1.48-4.38, p 0.001) and median SARS-CoV-2 IgG titres were significantly higher in patients with post-COVID-19 syndrome than in patients without symptoms (42.1, IQR 17.1-78.4 vs. 29.1, IQR 12.1-54.2 kAU/L, p 0.004). Female gender (OR 1.55, 95% CI 1.05-2.27), a proportional increase in the number of symptoms at the onset of COVID-19 (OR 1.81, 95% CI 1.59-2.05) and ICU admission OR 3.10, 95% CI 1.18-8.11) were all independent risk factors for post-COVID-19 syndrome. The same predictors also emerged in a subgroup of 231 patients with the serological follow-up available at the time of the interview alongside the proportional increase in anti-SARS-CoV-2 IgG (OR 1.01, 95% CI 1.00-1.02, p 0.04). Prospective follow-up could be offered to specific subgroups of COVID-10 patients, to identify typical symptoms and persistently high anti-SARS-CoV-2 IgG titres as a means of early detection of post-COVID-19 long-term sequelae.
Identifiants
pubmed: 34111579
pii: S1198-743X(21)00281-0
doi: 10.1016/j.cmi.2021.05.033
pmc: PMC8180450
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1507-1513Informations de copyright
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Clin Infect Dis. 2020 Nov 19;71(16):2249-2251
pubmed: 32306036
BMC Rheumatol. 2020 Oct 28;4:65
pubmed: 33123675
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet. 2020 Aug 22;396(10250):531
pubmed: 32791038
PLoS One. 2019 Feb 4;14(2):e0211532
pubmed: 30716129
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
Crit Care Med. 2012 Feb;40(2):502-9
pubmed: 21946660
Biomed Pharmacother. 2020 Jul;127:110195
pubmed: 32361161
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Clin Microbiol Infect. 2020 Nov;26(11):1448-1449
pubmed: 32712242
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
PLoS One. 2020 Dec 11;15(12):e0243882
pubmed: 33306721
Lancet. 2020 Oct 31;396(10260):1389-1391
pubmed: 33058777
J Neurol Sci. 2020 Dec 15;419:117179
pubmed: 33070003
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Open Forum Infect Dis. 2020 Oct 21;7(12):ofaa509
pubmed: 33403218
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
Front Psychiatry. 2020 Aug 07;11:790
pubmed: 32848952
Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S52-6
pubmed: 27481954
Clin Infect Dis. 2019 Sep 13;69(7):1192-1197
pubmed: 30561555
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
Brain Behav Immun. 2010 Oct;24(7):1209-17
pubmed: 20447453
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513